• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2:重新利用的药物和新型治疗方法——对化学结构、生物活性和毒理学筛选的见解

SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.

作者信息

Dehelean Cristina Adriana, Lazureanu Voichita, Coricovac Dorina, Mioc Marius, Oancea Roxana, Marcovici Iasmina, Pinzaru Iulia, Soica Codruta, Tsatsakis Aristidis M, Cretu Octavian

机构信息

Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.

Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.

出版信息

J Clin Med. 2020 Jul 2;9(7):2084. doi: 10.3390/jcm9072084.

DOI:10.3390/jcm9072084
PMID:32630746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7409030/
Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic represents the primary public health concern nowadays, and great efforts are made worldwide for efficient management of this crisis. Considerable scientific progress was recorded regarding SARS-CoV-2 infection in terms of genomic structure, diagnostic tools, viral transmission, mechanism of viral infection, symptomatology, clinical impact, and complications, but these data evolve constantly. Up to date, neither an effective vaccine nor SARS-CoV-2 specific antiviral agents have been approved, but significant advances were enlisted in this direction by investigating repurposed approved drugs (ongoing clinical trials) or developing innovative antiviral drugs (preclinical and clinical studies). This review presents a thorough analysis of repurposed drug admitted for compassionate use from a chemical structure-biological activity perspective highlighting the ADME (absorption, distribution, metabolism, and excretion) properties and the toxicophore groups linked to potential adverse effects. A detailed pharmacological description of the novel potential anti-COVID-19 therapeutics was also included. In addition, a comprehensible overview of SARS-CoV-2 infection in terms of general description and structure, mechanism of viral infection, and clinical impact was portrayed.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行是当前主要的公共卫生问题,全球都在为有效应对这场危机而努力。在SARS-CoV-2感染方面,从基因组结构、诊断工具、病毒传播、病毒感染机制、症状学、临床影响和并发症等方面都取得了显著的科学进展,但这些数据在不断演变。截至目前,既没有有效的疫苗,也没有SARS-CoV-2特异性抗病毒药物获得批准,但通过研究重新利用已批准药物(正在进行的临床试验)或开发创新抗病毒药物(临床前和临床研究),在这方面已经取得了重大进展。本综述从化学结构-生物活性的角度对用于同情用药的重新利用药物进行了全面分析,突出了其吸收、分布、代谢和排泄(ADME)特性以及与潜在不良反应相关的毒理学基团。还包括了新型潜在抗COVID-19疗法的详细药理学描述。此外,还对SARS-CoV-2感染在总体描述和结构、病毒感染机制以及临床影响方面进行了全面概述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28da/7409030/f3364456b8a3/jcm-09-02084-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28da/7409030/6f8924539271/jcm-09-02084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28da/7409030/f3364456b8a3/jcm-09-02084-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28da/7409030/6f8924539271/jcm-09-02084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28da/7409030/f3364456b8a3/jcm-09-02084-g004.jpg

相似文献

1
SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.严重急性呼吸综合征冠状病毒2:重新利用的药物和新型治疗方法——对化学结构、生物活性和毒理学筛选的见解
J Clin Med. 2020 Jul 2;9(7):2084. doi: 10.3390/jcm9072084.
2
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
3
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.抗 SARS-CoV-2 感染的 FDA 批准药物在雪貂中的抗病毒疗效。
mBio. 2020 May 22;11(3):e01114-20. doi: 10.1128/mBio.01114-20.
4
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效:III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
5
Safety profile of COVID-19 drugs in a real clinical setting.在真实临床环境中 COVID-19 药物的安全性概况。
Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28.
6
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?抗2019冠状病毒病病毒疗法的最新进展:我们取得了多大的进展?
Front Pharmacol. 2021 Mar 8;12:632677. doi: 10.3389/fphar.2021.632677. eCollection 2021.
7
Impact of repurposed drugs on the symptomatic COVID-19 patients.重新利用药物对有症状的 COVID-19 患者的影响。
J Infect Public Health. 2021 Jan;14(1):24-38. doi: 10.1016/j.jiph.2020.11.009. Epub 2020 Dec 7.
8
A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.关于正在进行的新型冠状病毒(COVID-19)大流行的潜在预防措施、疫苗和治疗手段的范围性洞察——全面综述
Front Pharmacol. 2021 Feb 26;11:590154. doi: 10.3389/fphar.2020.590154. eCollection 2020.
9
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2:洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
10
In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.洛匹那韦/利托那韦和羟氯喹在通常剂量下可达到的浓度对严重急性呼吸综合征冠状病毒 2 的体外活性。
Korean J Intern Med. 2020 Jul;35(4):782-787. doi: 10.3904/kjim.2020.157. Epub 2020 May 29.

引用本文的文献

1
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question.新冠疫情与三种药物的故事:是否进行药物再利用——这就是问题所在。
Viruses. 2025 Jun 23;17(7):881. doi: 10.3390/v17070881.
2
Advancements in the development of antivirals against SARS-Coronavirus.抗SARS冠状病毒抗病毒药物的研发进展。
Front Cell Infect Microbiol. 2025 Jan 23;15:1520811. doi: 10.3389/fcimb.2025.1520811. eCollection 2025.
3
Herbal concoction Unveiled: A computational analysis of phytochemicals' pharmacokinetic and toxicological profiles using novel approach methodologies (NAMs).

本文引用的文献

1
Pay attention to SARS-CoV-2 infection in children.关注儿童中的新型冠状病毒2型感染。
Pediatr Investig. 2020 Mar 17;4(1):1-4. doi: 10.1002/ped4.12178. eCollection 2020 Mar.
2
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎:一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
3
Anakinra in COVID-19: important considerations for clinical trials.阿那白滞素用于新型冠状病毒肺炎:临床试验的重要考量因素
草药配方揭秘:使用新型方法(NAMs)对植物化学物质的药代动力学和毒理学特征进行计算分析。
Curr Res Toxicol. 2023 Aug 12;5:100118. doi: 10.1016/j.crtox.2023.100118. eCollection 2023.
4
Drug Repurposing: a Shortcut to New Biological Entities.药物重新利用:通往新生物实体的捷径。
Pharm Chem J. 2022;56(9):1203-1214. doi: 10.1007/s11094-022-02778-w. Epub 2022 Dec 7.
5
Synthesis and Biological Evaluation of Umifenovir Analogues as Anti-SARS-CoV-2 Agents.作为抗SARS-CoV-2药物的乌米芬诺尔类似物的合成及生物学评价
ChemistrySelect. 2022 Aug 12;7(30):e202202097. doi: 10.1002/slct.202202097. Epub 2022 Aug 9.
6
Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats.在怀孕大鼠中,抗病毒药物瑞德西韦及其主要代谢物 GS-441524 的生物转化和胎盘转移。
EBioMedicine. 2022 Jul;81:104095. doi: 10.1016/j.ebiom.2022.104095. Epub 2022 Jun 4.
7
Ultraviolet-coupled advanced oxidation processes for anti-COVID-19 drugs treatment: Degradation mechanisms, transformation products and toxicity evolution.紫外线耦合高级氧化工艺处理抗 COVID-19 药物:降解机制、转化产物和毒性演变。
Chemosphere. 2022 Sep;303(Pt 1):134968. doi: 10.1016/j.chemosphere.2022.134968. Epub 2022 May 14.
8
Application of the advanced lung cancer inflammation index for patients with coronavirus disease 2019 pneumonia: Combined risk prediction model with advanced lung cancer inflammation index, computed tomography and chest radiograph.晚期肺癌炎症指数在2019冠状病毒病肺炎患者中的应用:晚期肺癌炎症指数、计算机断层扫描和胸部X线联合风险预测模型
Exp Ther Med. 2022 Jun;23(6):388. doi: 10.3892/etm.2022.11315. Epub 2022 Apr 12.
9
Molecular Docking and Dynamics Studies to Explore Effective Inhibitory Peptides Against the Spike Receptor Binding Domain of SARS-CoV-2.探索针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突受体结合域的有效抑制肽的分子对接和动力学研究
Front Mol Biosci. 2022 Jan 27;8:791642. doi: 10.3389/fmolb.2021.791642. eCollection 2021.
10
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.布洛芬、氟比洛芬、依托考昔或对乙酰氨基酚在体外或在小鼠中不影响 ACE2 表达和活性,也不会加重体外 SARS-CoV-2 感染。
Int J Mol Sci. 2022 Jan 19;23(3):1049. doi: 10.3390/ijms23031049.
Lancet Rheumatol. 2020 Jul;2(7):e379-e381. doi: 10.1016/S2665-9913(20)30160-0. Epub 2020 May 21.
4
COVID-19 and anosmia: A review based on up-to-date knowledge.新型冠状病毒肺炎与嗅觉障碍:基于最新知识的综述。
Am J Otolaryngol. 2020 Sep-Oct;41(5):102581. doi: 10.1016/j.amjoto.2020.102581. Epub 2020 Jun 2.
5
Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.味觉和嗅觉丧失是 2019 冠状病毒病的特征性症状。
Clin Infect Dis. 2021 Feb 16;72(4):682-685. doi: 10.1093/cid/ciaa799.
6
Age-dependent effects in the transmission and control of COVID-19 epidemics.年龄相关因素对 COVID-19 疫情传播和防控的影响。
Nat Med. 2020 Aug;26(8):1205-1211. doi: 10.1038/s41591-020-0962-9. Epub 2020 Jun 16.
7
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.皮下注射干扰素 β-1a 治疗 COVID-19:一项非对照前瞻性试验。
Int Immunopharmacol. 2020 Aug;85:106688. doi: 10.1016/j.intimp.2020.106688. Epub 2020 Jun 7.
8
Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak.实时 RT-PCR SARS-CoV-2 检测 panel 中的多重检测可以降低新型基因组变异导致的检测敏感性降低的风险,从而应对 COVID-19 大流行。
Int J Infect Dis. 2020 Aug;97:225-229. doi: 10.1016/j.ijid.2020.06.027. Epub 2020 Jun 12.
9
Interferon beta-1a for COVID-19: critical importance of the administration route.用于治疗新型冠状病毒肺炎的β-1a干扰素:给药途径的关键重要性
Crit Care. 2020 Jun 12;24(1):335. doi: 10.1186/s13054-020-03048-5.
10
Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.瑞德西韦与 SARS-CoV-2 RNA 依赖的 RNA 聚合酶潜在结合机制的结构基础。
J Phys Chem B. 2020 Aug 13;124(32):6955-6962. doi: 10.1021/acs.jpcb.0c04198. Epub 2020 Jun 23.